Comparative Pharmacology
Head-to-head clinical analysis: DUETACT versus ROSIGLITAZONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DUETACT versus ROSIGLITAZONE.
DUETACT vs ROSIGLITAZONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
DUETACT is a fixed-dose combination of pioglitazone, a thiazolidinedione that improves insulin sensitivity by activating peroxisome proliferator-activated receptor-gamma (PPAR-γ), and glimepiride, a sulfonylurea that stimulates insulin secretion from pancreatic beta cells by blocking ATP-sensitive potassium channels.
Selective agonist at peroxisome proliferator-activated receptor gamma (PPARγ), enhancing insulin sensitivity by increasing glucose uptake and storage, reducing hepatic glucose production, and improving lipid metabolism.
Initial dose: 30 mg pioglitazone/2 mg glimepiride orally once daily; titrate based on glycemic control; maximum dose: 45 mg pioglitazone/8 mg glimepiride daily.
4-8 mg orally once daily or divided twice daily; maximum 8 mg/day.
None Documented
None Documented
Clinical Note
moderateRosiglitazone + Gatifloxacin
"Rosiglitazone may increase the hypoglycemic activities of Gatifloxacin."
Clinical Note
moderateRosiglitazone + Rosoxacin
"Rosiglitazone may increase the hypoglycemic activities of Rosoxacin."
Clinical Note
moderateRosiglitazone + Levofloxacin
"Rosiglitazone may increase the hypoglycemic activities of Levofloxacin."
Clinical Note
moderateRosiglitazone + Trovafloxacin
"Rosiglitazone may increase the hypoglycemic activities of Trovafloxacin."
Pioglitazone: terminal half-life 3-7 hours (parent drug), 16-24 hours (active metabolites); clinical context: once-daily dosing sufficient due to active metabolites. Glimepiride: terminal half-life 5-8 hours; clinical context: supports once- or twice-daily dosing in type 2 diabetes.
Terminal elimination half-life is 3-4 hours. Clinically, this short half-life allows twice-daily dosing; steady-state is achieved within 2 days.
Pioglitazone is primarily excreted in feces (55%) as metabolites, with renal excretion accounting for 30% (primarily as metabolites and <5% unchanged). Glimepiride is excreted in urine (60% as metabolites, ~25% unchanged) and feces (40% as metabolites).
Primarily hepatic metabolism via CYP2C8; negligible renal excretion. Approximately 64% of dose excreted in urine (as metabolites) and 23% in feces over 96 hours. Less than 0.2% excreted unchanged in urine.
Category C
Category A/B
Thiazolidinedione/Sulfonylurea Combination
Thiazolidinedione